Research programme: polysarcosine DN TNF - INmune Bio
Alternative Names: pSar DN-TNFLatest Information Update: 15 Sep 2023
At a glance
- Originator INmune Bio
- Class Antineoplastics; Peptoids; Recombinant proteins
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
- Research Duchenne muscular dystrophy
Most Recent Events
- 02 Aug 2023 Research programme: polysarcosine DN TNF - INmune Bio is available for licensing as of 02 Aug 2023. https://inmunebio.com/contact-2/contact-us
- 31 Jul 2023 INmune Bio has patent protection for DN-TNF platform, before July 2023
- 02 Mar 2023 Early research in Duchenne muscular dystrophy in USA (Parenteral) (INmune Bio pipeline, July 2023)